Intraperitoneal and Intravenous Chemotherapy for Colon Cancer
Author Information
Author(s): W Scheithauer, GV Kornek, A Marczell, J Karner, G Salem, R Greiner, D Burger, F StogeP, J Ritschel, E Kovats, HM Vischer, B Schneeweiss, D Depisch
Primary Institution: University of Vienna
Hypothesis
Does combined intraperitoneal and intravenous chemotherapy yield better results than conventional therapy for resected colon cancer?
Conclusion
Combined intraperitoneal and intravenous chemotherapy with fluorouracil and leucovorin is a promising treatment strategy that reduces recurrence and improves survival in patients with resected stage III colon cancer.
Supporting Evidence
- Patients receiving the investigational arm had a 43% reduction in mortality rate.
- Combined treatment showed a significant improvement in disease-free survival.
- Adverse reactions were generally mild and less frequent in the investigational arm.
Takeaway
This study tested a new way to give chemotherapy for colon cancer and found that it helps patients live longer and have fewer relapses.
Methodology
Patients were randomly assigned to receive either standard therapy with fluorouracil and levamisole or a combination of fluorouracil and leucovorin administered both intravenously and intraperitoneally.
Limitations
The follow-up duration was limited, and the sample size for stage II patients was too small to draw definitive conclusions.
Participant Demographics
Patients had resected stage II or III colon cancer, with a median age of 63 years.
Statistical Information
P-Value
P=0.0005
Confidence Interval
95% confidence interval 26-70%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website